



#### NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO U.S. PERSONS

17 November 2017

#### **ASX RELEASE**

# **Oneview Healthcare PLC**

# Oneview Healthcare to raise approximately \$30 million via an Entitlement Offer and an Institutional Placement

Oneview Healthcare PLC (ASX: ONE) (**Oneview**) today announced the launch of an equity raising, comprising an accelerated pro-rata non-renounceable entitlement offer and an institutional placement.

## **Key Highlights**

- Approximately 15 million new CHESS Depositary Interests (New CDIs) to be issued at an offer price of A\$2.00 per security, representing:
  - o 7.45% discount to TERP1; and
  - 9.09% discount to the last close price of A\$2.20 as at Tuesday, 14 November 2017.
- Proceeds from the equity raising will be used to provide balance sheet flexibility to deliver on Oneview's growth strategy.
- Following successful completion of the equity raising, Oneview is expected to have a pro forma net cash position of A\$61.6 million as at 30 June 2017.

# **The Offer**

The Offer will comprise:

- a fully underwritten 1 for 4.35 accelerated pro rata non-renounceable entitlement offer, being the issue of approximately 12.5 million New CDIs to raise approximately A\$25 million (Entitlement Offer); and
- a fully underwritten institutional placement of approximately 2.5 million New CDIs to raise approximately A\$5 million (Placement)

(Entitlement Offer and Placement together, the Offer).

The Entitlement Offer will consist of an Institutional Entitlement Offer and a Retail Entitlement Offer.

The New CDIs will rank pari passu with existing Oneview CDIs on issue at the time of this announcement.

Upon completion of the Offer, Oneview will have approximately 69.4 million CDIs on issue.

# Commentary

Oneview's Interim Chairman, Joseph Rooney, said:

"We are pleased to announce the launch of this equity raising and provide both our existing securityholders and new investors the opportunity to support Oneview. We consider this equity raising to be an important measure to strengthen Oneview's balance sheet, allowing us to continue to invest in

<sup>&</sup>lt;sup>1</sup> TERP is the theoretical price at which Oneview CDIs should trade immediately after the ex-date for the Entitlement Offer and Institutional Placement. TERP is a theoretical calculation only and the actual price at which Oneview CDIs trade immediately after the ex-date for the Entitlement Offer and Institutional Placement depends on many factors and may not be equal to TERP.

technology and product enhancement across our portfolio. The Offer has been designed to allow eligible retail and institutional securityholders to participate whilst also providing an opportunity for new investors to join the register. The successful completion of this equity raising will position us for future growth and to respond to our expanding market opportunities as we broaden our product portfolio."

Oneview's CEO, James Fitter, added:

"The capital raising will provide us with financial flexibility to execute our business plan and deliver fresh growth, not just in relation to our core inpatient product but also to bring our other three new, substantially complete, products to market. We are very excited by the opportunities that our new Android platform will deliver and look forward to providing more operating system choice for our customers."

## Offer Details and Key Dates

#### Institutional Entitlement Offer

Eligible institutional securityholders with registered addresses in the offering jurisdictions will be invited to participate in the Institutional Entitlement Offer and Placement, which is being conducted today, Friday, 17 November 2017. Eligible institutional securityholders can choose to take up all, part or none of their entitlement.

Together with the Placement, institutional entitlements that eligible institutional securityholders do not take up by the close of the Institutional Entitlement Offer, and institutional entitlements that would otherwise have been offered to ineligible institutional securityholders, will be offered to eligible institutional securityholders who apply for New CDIs in excess of their entitlement, as well as to certain other eligible institutional investors, through an institutional shortfall bookbuild to be conducted concurrently with the Institutional Entitlement Offer and Placement.

#### Retail Entitlement Offer

Eligible retail securityholders with retail addresses in Australia, New Zealand and Ireland will be invited to participate in the Retail Entitlement Offer at the same offer price and offer ratio as under the Institutional Entitlement Offer and Placement. The Retail Entitlement Offer will open at 9:00am (Sydney time) on Thursday, 23 November 2017 and close at 5.00pm (Sydney time) on Monday, 4 December 2017 (Retail Offer Period).

Further details about the Retail Entitlement Offer will be set out in an information booklet (**Retail Offer Booklet**), which Oneview expects to lodge with the ASX and despatch by Thursday, 23 November 2017. The closing date for receipt of Entitlement and Acceptance Forms and Application Payments is 5.00pm (Sydney time) on Monday, 4 December 2017.

## **Key Offer Dates**

Key event	Date
Announcement of Institutional Entitlement Offer and Placement	Friday, 17 November 2017
Institutional Entitlement Offer and Institutional Placement closes	Friday, 17 November 2017
Trading halt lifted – CDIs recommence trading on ASX on an "ex-entitlement" basis	Monday, 20 November 2017
Record Date for determining entitlement to subscribe for New CDIs	7.00pm on Tuesday, 21 November 2017
Retail Entitlement Offer opens	Thursday, 23 November 2017
Settlement of Institutional Entitlement Offer and Placement	Tuesday, 28 November 2017
Allotment and normal trading of New CDIs under the Institutional Entitlement Offer and Placement	Wednesday, 29 November 2017
Retail Entitlement Offer closes	5.00pm on Monday, 4 December 2017
Allotment of New CDIs and despatch of holding statements under the Retail Entitlement Offer	Monday, 11 December 2017
Normal trading of New CDIs issued under the Retail Entitlement Offer	Tuesday, 12 December 2017

Note: The above timetable is indicative only and subject to change. Oneview, in conjunction with the sole lead manager and underwriter, reserves the right to amend any or all of these events, dates and times, subject to the Corporations Act 2001 (Cth), the ASX Listing Rules and other applicable laws. All times and dates are in reference to AEDT.

## Additional Information

Additional information regarding the Offer is contained in the investor presentation that Oneview released to the ASX today. The investor presentation also contains important information, including information about the risk factors and the foreign selling restrictions, with respect to the Offer. The Retail Information Booklet will be released separately and mailed to eligible retail securityholders.

You should seek appropriate professional advice before making any investment decision. If you have any questions about the Retail Entitlement Offer, please contact the Oneview Healthcare Entitlement Offer Information Line on 1300 145 340 (from within Australia) or +61 3 9415 4291 (from outside Australia) between 9.00am and 5.00pm (Sydney time), Monday to Friday during the Retail Offer Period.

# For further information please contact:

Mr Nick Brown

Company Secretary Tel: +61 2 9922 2720

Email: <a href="mailto:nbrown@oneviewhealthcare.com">nbrown@oneviewhealthcare.com</a>

**Mr Patrick Masterson** 

Company Secretary Tel: +353 1 524 1677

Email: pmasterson@oneviewhealthcare.com

3

#### **IMPORTANT NOTICES**

This release contains certain forward-looking statements. Examples of forward-looking statements used in this release include: "will", "provide", "execute", "deliver", "expect" and "designed". Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this release are based on assumptions and contingencies that are subject to change without notice. Forward-looking statements are not a guarantee of future performance and are subject to a variety of risks and uncertainties beyond Oneview's ability to control or predict, which could cause actual events or results to differ materially from those anticipated in such forward-looking statements.

This release does not include all available information on Oneview and should not be used in isolation as a basis to invest in Oneview. Any potential investors should refer to Oneview's other public releases and statutory reports and consult their professional advisers before considering investing in Oneview.

Determination of eligibility of investors for the purposes of the institutional or retail components of the Entitlement Offer is determined by reference to a number of matters, including legal and regulatory requirements, logistical and registry constraints and the discretion of Oneview and/or the Lead Manager. Each of Oneview and the Lead Manager and each of their respective affiliates disclaim any duty or liability (including for negligence) in respect of that determination and the exercise or otherwise of that discretion, to the maximum extent permitted by law.

This release has been prepared for publication in Australia and may not be released in the United States. This release does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this release have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States or to, or for the account or benefit of U.S. Persons (as defined in Rule 902 (k) under the U.S. Securities Act) except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws. The distribution of this announcement in other jurisdictions outside Australia may also be restricted by law and any such restrictions should be observed. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.